Compare TRTX & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRTX | EOLS |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.2M | 550.9M |
| IPO Year | 2015 | 2018 |
| Metric | TRTX | EOLS |
|---|---|---|
| Price | $7.78 | $9.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $9.83 | ★ $15.50 |
| AVG Volume (30 Days) | 773.7K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 11.55% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | $8.78 | $13.27 |
| Revenue Next Year | $4.14 | $17.62 |
| P/E Ratio | $41.05 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $7.57 | $3.86 |
| 52 Week High | $9.85 | $9.15 |
| Indicator | TRTX | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 69.65 |
| Support Level | $7.57 | $6.39 |
| Resistance Level | $8.74 | N/A |
| Average True Range (ATR) | 0.12 | 0.35 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 51.28 | 90.91 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.